Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMN AMN Healthcare Services	$22.67 +3.0%	$21.75	$17.45 ▼ $70.07	$865.75M	0.16	920,283 shs	1.16 million shs
ISEE IVERIC bio	$39.95	$38.88	$9.39 ▼ $39.99	$5.50B	1.06	3.62 million shs	N/A
MRVI Maravai LifeSciences	$2.12 +7.1%	$2.15	$1.67 ▼ $11.56	$539.19M	0.19	2.33 million shs	3.10 million shs
ZLAB Zai Lab	$29.40 +0.5%	$32.62	$16.01 ▼ $39.77	$3.24B	1.04	851,214 shs	1.15 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMN AMN Healthcare Services	+3.09%	+13.55%	+18.68%	-7.24%	-58.56%
ISEE IVERIC bio	0.00%	0.00%	0.00%	0.00%	0.00%
MRVI Maravai LifeSciences	+6.53%	0.00%	+15.85%	-50.00%	-79.73%
ZLAB Zai Lab	+0.55%	-5.01%	-0.47%	+8.65%	+46.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMN AMN Healthcare Services	4.3028 of 5 stars	3.1	1.0	0.8	4.3	3.2	1.7	1.9
ISEE IVERIC bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	4.0927 of 5 stars	4.1	1.0	0.0	4.4	1.9	0.8	1.3
ZLAB Zai Lab	2.4645 of 5 stars	3.4	1.0	0.0	0.0	3.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMN AMN Healthcare Services	2.25	Hold	$38.67	70.56% Upside
ISEE IVERIC bio	0.00	N/A	N/A	N/A
MRVI Maravai LifeSciences	2.18	Hold	$6.34	199.23% Upside
ZLAB Zai Lab	2.75	Moderate Buy	$47.37	61.11% Upside

Current Analyst Ratings Breakdown

Latest AMN, ZLAB, MRVI, and ISEE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2025	AMN AMN Healthcare Services	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $25.00
3/27/2025	ZLAB Zai Lab	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/25/2025	MRVI Maravai LifeSciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $5.00
3/21/2025	MRVI Maravai LifeSciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
3/21/2025	MRVI Maravai LifeSciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$8.00 ➝ $2.50
3/13/2025	ZLAB Zai Lab	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$44.00 ➝ $51.00
3/7/2025	ZLAB Zai Lab	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$55.00
3/4/2025	ZLAB Zai Lab	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/3/2025	MRVI Maravai LifeSciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $8.00
3/3/2025	ZLAB Zai Lab	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$29.00 ➝ $36.10
2/26/2025	MRVI Maravai LifeSciences	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMN AMN Healthcare Services	$2.85B	0.30	$6.35 per share	3.57	$18.56 per share	1.22
ISEE IVERIC bio	N/A	N/A	N/A	N/A	$4.43 per share	N/A
MRVI Maravai LifeSciences	$259.19M	2.08	$0.05 per share	41.71	$3.14 per share	0.68
ZLAB Zai Lab	$418.33M	7.75	N/A	N/A	$8.05 per share	3.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMN AMN Healthcare Services	-$146.98M	-$4.33	N/A	9.37	N/A	-4.93%	15.22%	4.72%	N/A
ISEE IVERIC bio	-$185.21M	-$1.76	N/A	N/A	N/A	N/A	-57.00%	-46.15%	N/A
MRVI Maravai LifeSciences	-$119.03M	-$1.02	N/A	N/A	N/A	-81.13%	-6.61%	-3.45%	N/A
ZLAB Zai Lab	-$334.62M	-$2.49	N/A	N/A	N/A	-76.14%	-36.97%	-27.10%	N/A

Latest AMN, ZLAB, MRVI, and ISEE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	MRVI Maravai LifeSciences	-$0.07	-$0.08	-$0.01	-$0.21	$44.01 million	$46.85 million
5/8/2025	Q1 2025	AMN AMN Healthcare Services	$0.19	$0.45	+$0.26	-$0.03	$670.08 million	$689.53 million
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.33	-$0.45	-$0.12	-$0.45	$118.40 million	$106.49 million
2/27/2025	Q4 2024	ZLAB Zai Lab	-$0.61	-$0.80	-$0.19	-$0.80	$110.15 million	$109.07 million
2/20/2025	Q4 2024	AMN AMN Healthcare Services	$0.52	$0.75	+$0.23	-$4.90	$694.38 million	$734.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMN AMN Healthcare Services	$1.20	5.29%	N/A	N/A	N/A
ISEE IVERIC bio	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMN AMN Healthcare Services	1.49	1.09	1.18
ISEE IVERIC bio	0.20	15.53	15.53
MRVI Maravai LifeSciences	0.89	10.74	9.94
ZLAB Zai Lab	N/A	3.01	2.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMN AMN Healthcare Services	99.23%
ISEE IVERIC bio	N/A
MRVI Maravai LifeSciences	50.25%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
AMN AMN Healthcare Services	0.93%
ISEE IVERIC bio	2.70%
MRVI Maravai LifeSciences	0.63%
ZLAB Zai Lab	13.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMN AMN Healthcare Services	4,230	38.19 million	37.72 million	Optionable
ISEE IVERIC bio	163	137.78 million	134.06 million	Optionable
MRVI Maravai LifeSciences	610	254.34 million	250.94 million	Optionable
ZLAB Zai Lab	1,950	110.33 million	94.24 million	Optionable

AMN, ZLAB, MRVI, and ISEE Headlines

Recent News About These Companies

Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

May 11 at 9:03 AM | seekingalpha.com

The Manufacturers Life Insurance Company Purchases 39,294 Shares of Zai Lab Limited (NASDAQ:ZLAB)

May 11 at 4:32 AM | marketbeat.com

Zai Lab First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

May 10 at 3:50 PM | finance.yahoo.com

Bridgefront Capital LLC Acquires Shares of 11,303 Zai Lab Limited (NASDAQ:ZLAB)

May 10 at 5:30 AM | marketbeat.com

Bayesian Capital Management LP Takes $405,000 Position in Zai Lab Limited (NASDAQ:ZLAB)

May 10 at 5:05 AM | marketbeat.com

Which Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Zai Lab Limited Stock?

May 9, 2025 | aaii.com

Zai Lab Ltd (ZLAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

May 9, 2025 | finance.yahoo.com

Hsbc Holdings PLC Buys Shares of 18,840 Zai Lab Limited (NASDAQ:ZLAB)

May 9, 2025 | marketbeat.com

Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say

May 8, 2025 | zacks.com

Zai Lab Limited Files Q1 2025 Form 10-Q with SEC

May 8, 2025 | tipranks.com

Zai Lab Reports Strong Q1 2025 Results and Promising Oncology Advances

May 8, 2025 | tipranks.com

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

May 8, 2025 | businesswire.com

Bellevue Group AG Acquires Shares of 13,000 Zai Lab Limited (NASDAQ:ZLAB)

May 7, 2025 | marketbeat.com

Raymond James Financial Inc. Makes New $1.03 Million Investment in Zai Lab Limited (NASDAQ:ZLAB)

May 7, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Makes New $3.31 Million Investment in Zai Lab Limited (NASDAQ:ZLAB)

May 6, 2025 | marketbeat.com

Zai Lab Limited (ZLAB): Among the Best Breakout Stocks to Buy According to Analysts

May 5, 2025 | insidermonkey.com

Envestnet Asset Management Inc. Buys New Shares in Zai Lab Limited (NASDAQ:ZLAB)

May 4, 2025 | marketbeat.com

RA Capital Management L.P. Buys Shares of 1,295,040 Zai Lab Limited (NASDAQ:ZLAB)

May 3, 2025 | marketbeat.com

Zai Lab (ZLAB) to Release Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

Geode Capital Management LLC Boosts Position in Zai Lab Limited (NASDAQ:ZLAB)

May 3, 2025 | marketbeat.com

Wells Fargo & Company MN Grows Stake in Zai Lab Limited (NASDAQ:ZLAB)

May 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMN, ZLAB, MRVI, and ISEE Company Descriptions

AMN Healthcare Services NYSE:AMN

$22.67 +0.67 (+3.05%)

Closing price 05/12/2025 03:59 PM Eastern

Extended Trading

$22.12 -0.56 (-2.45%)

As of 07:26 AM Eastern

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

IVERIC bio NASDAQ:ISEE

IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.

Maravai LifeSciences NASDAQ:MRVI

$2.12 +0.14 (+7.07%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$2.12 +0.00 (+0.24%)

As of 07:36 AM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Zai Lab NASDAQ:ZLAB

$29.40 +0.16 (+0.55%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$29.68 +0.29 (+0.97%)

As of 07:15 AM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time